CHICAGO, Oct. 26, 2026 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that it will release its results for the third quarter 2026 on Monday, November 9, 2026.

Management will host a webcast and conference call on November 9, 2026, at 9:00 a.m. ET to discuss the results and provide a business update. The conference call will be available via public webcast through the Public Shareholders section of GCM Grosvenor’s website at www.gcmgrosvenor.com/public-shareholders and a replay will be available on the website soon after the call’s completion for at least seven (7) days.

To register for the call, visit www.gcmgrosvenor.com/public-shareholders.

About GCM Grosvenor

GCM Grosvenor (Nasdaq: GCMG) is a global alternative asset management solutions provider with approximately $97 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return strategies. Specializing in alternatives for more than 50 years, the firm serves a global institutional and individual client base through a team of approximately 550 professionals. GCM Grosvenor is headquartered in Chicago, with offices in New York, Toronto, London, Frankfurt, Tokyo, Hong Kong, Seoul, and Sydney. For more information, visit: gcmgrosvenor.com

Source: GCM Grosvenor

Public Shareholders Contact
Stacie Selinger
sselinger@gcmlp.com
312-506-6583

Media Contact
Dana Gorman
H/Advisors (on behalf of GCM Grosvenor)
dana.gorman@h-advisors.global
212-371-5999

Schemes expected to become effective October 27, 2026; new Critical Metals Corp shares expected to begin trading on Nasdaq November 6, 2026

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals exploration and mining company, today announced that the Supreme Court of Western Australia (the “Court”) has approved the Company’s proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium”).

Under the proposed transaction, Critical Metals Corp would acquire 100% of the issued share capital of European Lithium and all of European Lithium’s listed options by way of Court-approved schemes of arrangement under Part 5.1 of the Australian Corporations Act 2001 (Cth), comprising a scheme between European Lithium and its shareholders (the “Share Scheme”) and a scheme between European Lithium and the holders of its listed options (ASX: EUROC) (the “Option Scheme”, and together with the Share Scheme, the “Schemes”). The consideration payable under each Scheme is to be satisfied by the issue of new ordinary shares in Critical Metals Corp.

Court Approval

European Lithium has announced that on October 26, 2026, the Court made orders approving the Schemes. The approval follows the vote by European Lithium shareholders and option holders in favor of the Schemes on October 22, 2026.

Critical Metals Corp intends to rely on the Court’s approval of the Schemes to qualify for the exemption from registration under section 3(a)(10) of the U.S. Securities Act of 1933, as amended, in connection with the issue of new Critical Metals Corp shares under the Schemes.

Effective Date and Implementation

The Schemes will become legally effective once an office copy of the Court orders is lodged with the Australian Securities and Investments Commission, which European Lithium expects to do on October 27, 2026. Trading in European Lithium shares and options on the ASX is expected to be suspended from the close of trading that day.

The remaining key dates are expected to be:

  • October 27, 2026: Effective date and last day of trading of European Lithium shares and options on the ASX
  • October 29, 2026: Record date for entitlements to the scheme consideration
  • November 5, 2026: Implementation date, issue of new Critical Metals Corp shares to European Lithium securityholders
  • November 6, 2026: New Critical Metals Corp shares expected to begin trading on Nasdaq, and European Lithium removed from the ASX Official List

All dates refer to time in Perth, Western Australia, are indicative only and subject to change. Any changes will be announced by European Lithium on the ASX. For further details, including the full timetable and next steps, please refer to European Lithium’s announcement to the ASX, “Court Approval of Schemes,” dated October 26, 2026.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next-generation technologies for Europe and its Western world partners. Its flagship Project, Tanbreez, is one of the world’s largest rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations, including with respect to the proposed acquisition of European Lithium and the anticipated timetable for and implementation of the Schemes. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: ir@criticalmetalscorp.com
Media: pr@criticalmetalscorp.com

  • Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade).
  • The objective response rate (ORR) based on Response Assessment in Neuro-Oncology criteria (RANO) 2.0 was 40.0% (8/20) in high-grade glioma, including 3 Complete Responses (CRs), and 42.9% (3/7) in low-grade glioma, including 1 CR.
  • Deep responses (>80% tumor burden reduction) were reported in 87.5% (7/8) of responders with high-grade glioma and 66.7% (2/3) of responders with low-grade glioma.
  • Of the three patients previously treated with a BRAF inhibitor, two achieved a Partial Response (PR) and one had Stable Disease (SD).
  • NXP200 demonstrated a manageable safety profile.

Fort Lee, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today provided highlights from the oral presentation of positive, expanded data from the Phase 1b study for NXP200, a second-generation, paradox-breaker BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas at the 2026 European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain.

Oral Presentation Highlights

  • As of the May 4, 2026 cutoff, 27 efficacy-evaluable patients with recurrent or progressive BRAF V600 glioma were treated with NXP200 monotherapy, including 20 patients with high-grade glioma and 7 with low-grade glioma.
  • Treatment with NXP200 resulted in an ORR of 40.0% in the high-grade glioma cohort, including 3 CRs (one preliminary CR) and 42.9%, including one confirmed CR, in the low-grade glioma cohort; responses were assessed based on RANO 2.0 criteria.
  • Deep responses (>80% tumor burden reduction) were achieved in 87.5% (7/8) of responders with high-grade glioma and 66.7% (2/3) of responders with low-grade glioma. Notably, among the three patients previously treated with a BRAF inhibitor, two achieved a partial response and one had stable disease. 81.5% (22/27) of patients achieved tumor reduction and the Disease Control Rate (ORR plus SD) was 85.2% (23/27).
  • In patients with high-grade glioma, the median duration of response was 6.97 months, and the median overall survival was 17.15 months; in patients with low-grade glioma, the median duration of response and overall survival had not been reached. 12-month survival was 95% and 100% in the high-grade and low-grade glioma cohorts, respectively.
  • Among 28 safety-evaluable patients, 14.3% experienced a Grade 3 or higher treatment-related adverse event. One serious adverse event (SAE) was reported (intracranial pressure increased), which was not related to treatment. No treatment-related adverse event resulted in treatment discontinuation or death.
  • The Phase 1b study is being conducted by Haisco Pharmaceutical Group in China. In June 2026, Nuvectis in-licensed exclusive worldwide, ex-Greater China rights to NXP200 from Haisco.
  • In September 2026, NXP200 was granted Breakthrough Therapy Designation for the treatment of patients with BRAF V600-mutated, recurrent or progressive high-grade glioma by China’s Center for Drug Evaluation (CDE). In April 2026, the project was officially selected as a pilot project under the “Pediatric Anti-tumor Drug R&D Encouragement Pilot Scheme (Starlight Program)” for the indication of pediatric BRAF V600-mutated recurrent or progressive glioma by CDE.
  • The presentation is available on Nuvectis’ website at www.nuvectis.com.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “We congratulate our partner Haisco on these robust results with NXP200. The rate and durability of the responses reported with single-agent NXP200 in patients with recurrent or progressive gliomas are very encouraging, given the depth of the observed responses, which include CRs and PRs with >80% tumor burden reduction, together with the ability to induce responses in patients previously treated with a BRAF inhibitor while maintaining a manageable safety profile. We are excited about the emerging clinical profile of NXP200, which demonstrates the potential of NXP200 to become a differentiated, best-in-class, second-generation, paradox-breaker BRAF inhibitor. We look forward to further updates from the ongoing Phase 1b program, including in additional tumor types, and we remain on track to submit a U.S. IND for NXP200 by the end of this year.”

About NXP200

NXP200 is an oral paradox-breaking (second generation) BRAF inhibitor designed to block the BRAF pathway without triggering paradoxical activation that is seen with first-generation BRAF inhibitors. To date, NXP200 has demonstrated single-agent clinical activity, including in heavily pre-treated patients as well as in patients previously treated with BRAF inhibitors, against progressive gliomas and other tumor types including non-small cell lung, colorectal and papillary thyroid cancers.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.

The company’s lead drug candidate is NXP100 (ciprocopan), a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “could”, “estimate”, “expect”, “intend”, “seek”, “may”, “might”, “plan”, “potential”, “predict”, “project”, “target”, “aim”, “should”, “will”, “would”, or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the approvability and market potential of our pipeline products, the emerging clinical profile of NXP200, and the potential of NXP200 based on its preliminary results. Forward looking statements are based on Nuvectis’ current expectations, estimates, and projections and past interpretations of data and information available, including pharmacokinetics, pharmacodynamics, and the preliminary clinical safety and efficacy data generated to date for NXP200. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled “Risk Factors” in Nuvectis’ second quarter 2026 Form 10-Q and Nuvectis’ other public filings with the U.S. Securities and Exchange Commission (“SEC”). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’ expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Combined company would operate two distinct businesses under one parent: Opifex’s creator-economy platform and Safe Harbor’s established cannabis financial services business

Technology pioneer Greg Newman to serve as Chairman of the combined company

Transaction designed to support Safe Harbor’s plan to maintain its Nasdaq listing; Nasdaq has granted a second compliance period through April 19, 2027

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor (“Safe Harbor” ) (Nasdaq: SHFS), a fintech platform serving the banking, lending and financial services needs of the regulated cannabis and hemp industries, announced that it has signed a non-binding term sheet with Opifex Media Inc. (“Opifex”), a Beverly Hills, California-based media holding company focused on the creator economy, for a proposed business combination in which Opifex would become a wholly owned subsidiary of Safe Harbor (the “Proposed Transaction”). Following the closing, the combined company would remain listed on The Nasdaq Stock Market LLC (“Nasdaq”) under a new name to be determined. 

The Proposed Transaction is intended to create a public holding company with two distinct primary businesses, each pursuing its own growth strategy. Opifex would bring a portfolio of creator-economy businesses across publishing, music and video. Safe Harbor would continue to operate its cannabis-focused fintech platform and serve its clients and financial institution partners without interruption. For stockholders, the Proposed Transaction is designed to add a new growth platform, support Safe Harbor’s plan to maintain its Nasdaq listing, and create the opportunity for long-term value.

“Today’s announcement is an important step for Safe Harbor and our stockholders,” said Terry Mendez, Chief Executive Officer and Chief Financial Officer of Safe Harbor. “This proposed combination is intended to bring a growth-oriented creator-economy platform into our public company and to meet Nasdaq listing standards at closing. Greg Newman brings decades of experience building and scaling technology companies to the combined company’s board, and we believe this combination creates a compelling path forward for our stockholders.”

About Opifex and the Creator Economy Opportunity

Opifex acquires, operates and grows established creator-economy businesses across publishing, music and video, connecting them through a shared creator and data platform. The company focuses on verified human content and uses AI to improve operational efficiency, not to create content, while helping creators monetize through audiences, brands, subscriptions, licensing and media campaigns. By integrating these businesses, Opifex seeks to create a unified ecosystem that expands creator reach, strengthens first-party data and builds multiple revenue streams from the same creator-economy infrastructure.

According to Goldman Sachs Research, the creator economy was approximately $250 billion in 2023 and could reach approximately $480 billion by 2027. Opifex believes creator-led monetization continues to take share across advertising, commerce and subscriptions, and that high-quality, verified human content is becoming increasingly valuable as AI developers enter into content licensing agreements with publishers.

Opifex is led by Chairman Greg Newman. Mr. Newman is a serial entrepreneur and technology pioneer whose four-decade career spans foundational innovations in digital video and e-commerce, early backing of Baidu, and leadership of ventures shaping space power, the creator economy, sustainable energy and consumer technology. A former Fortune 500 executive and accomplished investor, Mr. Newman has helped build companies from the earliest days of the internet through major exits and global growth, while continuing to lead ambitious businesses at the forefront of innovation. His experience includes the founding team of Macromedia, leading QuickTime at Apple, building the Oracle Commerce Server, serving as an early institutional investor and board director of Baidu through its 2005 Nasdaq IPO, and co-founding C2B Technologies, which was acquired by Inktomi in 1998.

“The creator economy represents a significant opportunity to build a portfolio of complementary media businesses with established audiences and valuable intellectual property,” said Mr. Newman. “Our strategy is to acquire and grow platforms that serve creators, connect their audiences and create additional opportunities for monetization. We believe a combination with Safe Harbor provides the right public-company foundation for that vision, and we are committed to supporting the continued operation of Safe Harbor’s cannabis financial services business.”

Safe Harbor’s Cannabis Financial Services Business Continues

Safe Harbor will continue to operate its cannabis-focused fintech platform, delivering compliant banking, lending and business solutions to cannabis operators, as well as the infrastructure and compliance services financial institutions need to operate and scale cannabis banking programs. Since inception, Safe Harbor has supported the processing of more than $36 billion in cannabis-related transactions across 41 states and territories. The Proposed Transaction is not expected to change the services Safe Harbor provides to its clients and financial institution partners.

Key Terms of the Non-Binding Term Sheet

Structure. Opifex would merge with a newly formed, wholly owned subsidiary of Safe Harbor, and Opifex security holders would receive newly issued shares of Safe Harbor’s common stock, or, if the parties agree after consulting with Nasdaq, a combination of common stock and non-voting convertible preferred stock. The Proposed Transaction is expected to be accounted for as a reverse acquisition.

Ownership. At closing, Opifex security holders would own 85% and Safe Harbor’s existing stakeholders (e.g., holders of common stock, Series B Preferred Stock (on an as-converted basis), warrants, options and restricted stock units) would own 15% of the combined company on a fully diluted basis, before any capital raised at closing and any equity incentive plan reserve. However, the Safe Harbor allocation described above may be adjusted within a range of 12.5% to 17.5% to reflect Safe Harbor’s valuation at closing, as supported by an independent fairness opinion.

Valuation. Opifex will deliver a proposed valuation, together with its financial statements and supporting analysis, within 15 business days. The term sheet contemplates an Opifex valuation of not less than $50 million, subject to an independent valuation and fairness opinion delivered to Safe Harbor’s Board of Directors.

Contingent Value Right. The parties intend to negotiate a contingent value right for Safe Harbor’s existing stakeholders relating to Safe Harbor’s cannabis financial services business as part of the definitive agreements.

Equity Line of Credit. Safe Harbor does not intend to draw on its existing equity line of credit with CREO Capital until the closing of the Proposed Transaction.

Series B Preferred Securities. The term sheet contemplates the parties making arrangements under which all outstanding Series B Preferred Securities would convert into common stock at closing. These arrangements require entering into agreements with, and obtaining consents from, and waivers of Series B holders of transaction documents.

Capital and Nasdaq Listing. The parties intend for the combined company to meet applicable Nasdaq listing requirements at closing, including through a registered equity financing to investors who are not affiliates of either party, if necessary, and a direct investment of up to $1.0 million, subject to stockholder approval. Safe Harbor would seek stockholder approval of a reverse stock split to the extent needed to meet Nasdaq’s bid price requirement.

Equity Incentive Plan. At closing, the combined company would adopt an equity incentive plan, subject to stockholder approval, with a reserve equal to 10% of fully diluted shares.

Governance. The combined company’s five-member board would include Mr. Newman as Chairman, one additional Opifex designee, two independent directors designated by Opifex and approved by Safe Harbor’s Nominating and Corporate Governance Committee, and one director from Safe Harbor. Opifex would designate the combined company’s officers.

Timing and Conditions. The parties intend to negotiate a definitive agreement and to close the Proposed Transaction before April 19, 2027. Closing would be subject to, among other things, the negotiation of a definitive agreement, satisfactory due diligence findings by both parties, the required consents and agreements with holders of the Series B Securities, the completion of Opifex’s audited financial statements, an independent valuation and fairness opinion, Safe Harbor stockholder approval, Nasdaq approval, completion of any required financing and other customary conditions. The term sheet includes a 45-day exclusivity period.

As previously announced, on October 20, 2026, Nasdaq granted Safe Harbor an additional 180-day compliance period, through April 19, 2027, to regain compliance with the $1.00 minimum bid price requirement.

The independent members of the Board of Directors of Safe Harbor have approved entry into the term sheet. The term sheet is non-binding, except for certain customary provisions such as exclusivity and confidentiality, and does not obligate either party to complete the Proposed Transaction. There can be no assurance that a definitive agreement will be executed or that the Proposed Transaction will be completed on the terms described above or at all.

About Opifex Media
Opifex Media Inc. is a Beverly Hills, California-based holding company that acquires, operates and grows businesses across the creator economy, including publishing, music and video. www.opifexmedia.com

About Safe Harbor:
Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has assisted in the processing of more than $36 billion in cannabis-related depository funds across 41 states and territories. Through its proprietary Cannabis Banking Solutions™ Platform, and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking to long-term growth, Safe Harbor provides real solutions and personal support, built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Solicitation Material
This communication may be deemed to be solicitation material in connection with the proposals to be submitted to Safe Harbor’s stockholders at a meeting of stockholders seeking approval of certain matters in connection with the Proposed Transaction (the “Stockholder Meeting”). In connection with the proposals, Safe Harbor may file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which will include a proxy statement of Safe Harbor and a prospectus (the “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, Safe Harbor will mail the definitive Proxy Statement/Prospectus to its stockholders. INVESTORS AND SECURITY HOLDERS OF SAFE HARBOR ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SAFE HARBOR, OPIFEX, THE PROPOSED TRANSACTION AND THE PROPOSALS. Investors and security holders may obtain free copies of the Registration Statement, the Proxy Statement/Prospectus and other documents that Safe Harbor files with the SEC, when available, at the SEC’s website (www.sec.gov) or from Safe Harbor by accessing information included on Safe Harbor’s website (ir.shfinancial.org), which is not incorporated by reference herein.

Participants in the Solicitation
Safe Harbor, Opifex and their respective directors and certain of their respective executive officers may be deemed participants in the solicitation of proxies from Safe Harbor’s stockholders in connection with the Proposed Transaction. Information about Safe Harbor’s directors and executive officers, including their ownership of Safe Harbor securities, appears in Safe Harbor’s proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on May 8, 2026 (under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Compensation Discussion and Analysis”), and in its Annual Report on Form 10-K filed with the SEC on April 15, 2026. Changes in their holdings since those dates have been or will be reflected in Forms 3, 4, or 5 filed with the SEC. Information about Opifex’s directors and executive officers, and additional information about all participants and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Proxy Statement/Prospectus and other relevant materials filed with the SEC when they become available. These documents can be obtained free of charge as described above.

No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Cautionary Statement Regarding Forward-Looking Statements:
Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations and guidance relating to Safe Harbor’s services; Safe Harbor’s growth prospects and Safe Harbor’s market size; Safe Harbor’s projected financial and operational performance, including relative to its competitors and historical performance; success or viability of new product and service offerings Safe Harbor may introduce in the future; the impact volatility in the capital markets, which may adversely affect the price of Safe Harbor’s securities; the outcome of any legal proceedings that have been or may be brought by or against Safe Harbor; the execution of definitive agreements for the Proposed Transaction or the closing thereof; the Stockholder Meeting; and other statements regarding Safe Harbor’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, without limitation: the occurrence of any event, change or other circumstances that could give rise to the termination of the term sheet or prevent the execution of any definitive agreements with respect to the Proposed Transaction; the inability to complete the Proposed Transaction due to the failure to obtain the required stockholder approvals or any other required agreements, approvals or consents, including the consent of the holders of the Series B Preferred Stock required under the Series B transaction documents; the inability to obtain the required financing to complete the Proposed Transaction or to satisfy other conditions to closing; changes to the proposed structure of the Proposed Transaction that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining any required approval of the Proposed Transaction; SHF’s ability to regain compliance with the Nasdaq minimum bid price requirement by April 19, 2027; dilution to SHF’s existing stockholders; Opifex’s ability to complete its pending acquisitions and deliver audited financial statements; and other risks and uncertainties described from time to time in Safe Harbor’s filings with the SEC. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:
ir@SHFinancial.org 

Safe Harbor Media Relations Contact:
safeharbor@kcsa.com

To the Nasdaq Copenhagen

26 October 2026

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 23 October 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Totalkredit A/S

Attachments

DALLAS, Oct. 26, 2026 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST; SATA; SATS) (“Strive” or the “Company”) today announced that it has entered into a sales agreement pursuant to which Strive may issue and sell shares of its 15.00% Series A Perpetual SATS Preferred Stock, $0.001 par value per share (the “SATS Stock”), having an aggregate offering price of up to $1.0 billion (the “ATM Program”).

Strive intends to use the net proceeds from the ATM Program for general corporate purposes, including, among other things, the acquisition of bitcoin and bitcoin-related products and for working capital, the purchase of income generating assets to grow the Company’s business, other capital expenditures, and/or repurchases of shares of the Company’s Class A common stock, par value $0.001 per share (the “Class A Common Stock”) or its Variable Rate Series A Perpetual Preferred Stock, par value $0.001 per share (the “SATA Stock”). Strive may also use such proceeds to fund acquisitions of businesses, assets or technologies that complement our current business, for the payment of cash dividends declared or expected to be declared by Strive’s board of directors from time to time on shares of any class or series of Strive’s preferred stock then outstanding, or for repayment of future indebtedness.

The SATS Stock, subject to the terms and conditions of the sales agreement, may be sold by the sales agents by any method that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended or any other method permitted by law.

The sale of SATS Stock under the ATM Program is only offered pursuant to a prospectus supplement, filed with the Securities and Exchange Commission on October 26, 2026 under the existing automatic shelf registration statement, which became effective on September 15, 2025 (File No. 333-290252), and the base prospectus contained therein.

About Strive

Strive is a structured finance company focused on disciplined capital allocation and long-term value creation. We have strategically adopted bitcoin as our hurdle rate for capital deployment because of our fiduciary duty to maximize long-term value for stockholders and compound purchasing power over time.

Strive Asset Management, LLC, a direct, wholly owned subsidiary of Strive and an SEC-registered investment adviser, manages over $2.8 billion in assets.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, express or implied statements regarding the outlook and expectations of Strive and its subsidiaries, the strategic benefits and financial benefits of the merger transaction with Semler Scientific, Inc. (the “merger transaction”), including the expected impact of the merger transaction on Strive’s future financial performance and the ability to successfully integrate the combined businesses, and the anticipated use of proceeds from the offering. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” “predict,” “potential,” “assume,” “forecast,” “target,” “budget,” “outlook,” “trend,” “guidance,” “objective,” “goal,” “strategy,” “opportunity,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgments of Strive and its management team about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements as a result of various important factors. Other risks, uncertainties and assumptions, include, among others, the following:

  • the outcome of any legal proceedings that may be instituted against Strive or its subsidiaries;
  • the possibility that the anticipated benefits of the merger transaction are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement;
  • the diversion of management’s attention from ongoing business operations and opportunities;
  • dilution caused by Strive’s issuance of additional shares of its SATS Stock, Class A Common Stock or SATA Stock;
  • potential adverse reactions of Strive’s clients and customers or changes to business or employee relationships, including those resulting from the completion of the merger transaction; and
  • other factors that may affect future results of Strive or the future trading performance of its SATS Stock, Class A Common Stock or SATA Stock.

These factors are not necessarily all of the factors that could cause Strive’s actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive’s results.

Although Strive believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that the actual results of Strive will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive with the SEC.

The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive or its businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements contained in this press release speak only as of the date hereof, and Strive undertakes no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.  

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Strive Media Contact:
media@strive.com

Investor Contact:
ir@strive.com

Source: Strive, Inc.

MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation

Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.

Completion of this stage moves the initiative, announced in June 2026, from launch to an initial assessment of screening predictions. The predictions have not been experimentally validated and serve only as a starting point for evaluating potential follow-up research within MitoCareX’s small-molecule discovery programs.

“We believe that completing this first screening stage is an important step in translating our initiative with Boltz into research insights,” said David Palach, Chief Executive Officer of Nexentis. “We are focused on advancing proprietary discovery programs through disciplined, evidence-based decisions. These initial predictions give us a basis for planning next steps, and further validation will be essential to determining their significance.”

The initiative combines MitoCareX’s proprietary drug-discovery capabilities with Boltz’s AI models to identify potential small-molecule starting points for selected discovery programs. MitoCareX retains control over its discovery programs and any small-molecule candidates it advances through the initiative.

Further scientific assessment and validation will determine whether the preliminary predictions support advancing any program. No assurance can be given that any compound identified through the initiative will be advanced into preclinical or clinical development.

About MitoCareX Bio Ltd.

MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug-discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “could,” “potential” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the significance of the preliminary computational predictions from the initial screening stage under MitoCareX’s drug-discovery initiative with Boltz; the potential for further computational analysis, experimental investigation and validation of such predictions; the assessment of next research steps and follow-up research opportunities within MitoCareX’s small-molecule discovery programs; the potential identification and advancement of small-molecule starting points or candidates; and the potential contribution of the initiative to MitoCareX’s broader discovery strategy. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, market and other conditions; our history of losses, our need for additional capital to fund our operations and our potential inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the risk that computational or AI-generated predictions may not be confirmed by experimental testing or may not identify viable candidates; our dependence on third-party collaborators, including Boltz, and their technologies; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates, including our renewable energy investments; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of the Nasdaq Capital Market; and the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026, and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

To the Nasdaq Copenhagen

26 October 2026

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 23 October 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis.

As of October 21, 2026, BlackRock, Inc.’s aggregate holding of share capital amounts to 5.00% (previously 4.99%), comprising 4.99% of share capital attached to shares and 0.01% of share capital through financial instruments.

The full notification from BlackRock, Inc. is attached to this announcement.

Attachments

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — SPARC AI Inc. (CSE: SPAI; OTCQB: SPAIF; Frankfurt: 5OV0) (“SPARC AI” or the “Company”), a defense technology company, today announced that it has entered into a Memorandum of Understanding (“MOU”) with a major drone original equipment manufacturer (“OEM”) and supplier in Europe.

Highlights:

  • Signed MOU with Drone OEM in Europe
  • Expansion of Overwatch into Fixed-Wing platforms
  • Integration of Overwatch Intelligence, a consolidated view of connected aircraft
  • New Opportunities Beyond Defense
  • Field proven in Ukraine and the Middle East by operators on their own aircraft

Under the MOU the manufacturer will integrate and evaluate Overwatch, the Company’s positioning network for GPS-denied environments, on two new fixed-wing unmanned aerial vehicles (“UAVs”), with a defined path to commercial deployment once testing has been validated. Due to the highly security-sensitive nature of the agreement, the identity of the manufacturer and the jurisdiction, which is in Europe, are not being disclosed. The MOU is one of several engagements the Company has under way with drone manufacturers and end-user operators in the region, which range from evaluation of Overwatch on their platforms through to commercial discussions, and the Company expects to provide further updates as these progress.

The fixed-wing manufacturer will conduct independent testing and validation with SPARC AI providing engineering, training and standby support during the testing program. The MOU is structured so that integration and evaluation lead directly to commercial deployment.

The program represents the first integration of Overwatch on these two fixed-wing UAV platforms. Fixed-wing aircraft typically operate over greater distances and for longer durations than multirotor drones, increasing the importance of reliable positioning when GPS signals are unavailable denied or downgraded

Fleet-Wide Positioning Intelligence

The integration also incorporates Overwatch Intelligence, the Company’s platform for consolidating positioning data from multiple connected drones and UAVs into a unified operational picture

Overwatch Intelligence is designed to provide mission commanders with a consolidated view of connected aircraft, including their positions, observation data and movement history on a single map delivering fleet-wide intelligence in GPS denied environments.

This capability is intended to support coordinated operations in which maintaining situational awareness across multiple aircraft is critical.

Field Proven by Operators on Their Own Aircraft

The MOU follows independently verified live trials of Overwatch under GPS jamming in Ukraine and GPS spoofing in the Middle East. These were run by the operators themselves, on their own aircraft and at their own locations, rather than by SPARC AI on a demonstration airframe.

Opportunities Beyond Defense/ Advancing Commercial Engagements

Overwatch is a dual-use product with applications across defense, commercial and emergency response markets.

The same network that positions a drone under jamming also serves operators who need reliable positioning where GPS is unavailable or unreliable including inside and around critical infrastructure, in urban canyons and during disaster response. The Company is receiving interest in Overwatch for commercial use cases alongside its defense engagements and intends to pursue these opportunities.

Following a successful validation of Overwatch, SPARC AI has also entered into an agreement with a regional advisory firm to support and advance both defense and commercial activities in the Middle East.

As described above, a government ministry flew Overwatch on its own government-owned drones under GPS spoofing conditions, obtaining the position of the aircraft and then the coordinates of a target. The advisory firm will support SPARC AI in converting that validation into commercial engagements with government and defense customers in the region.

About SPARC AI Inc.

SPARC AI is a defense technology company solving for assured positioning in GNSS-denied environments. Its flagship product, Overwatch, is a platform that ingests telemetry from drones and other systems and platforms and returns absolute latitude and longitude — no onboard software, no edge hardware, and no reliance on GPS. Delivered as a stateless service, Overwatch gives commercial and defense operators dependable positioning enabling navigation and geospatial intelligence wherever satellite signals are jammed, spoofed, or unavailable.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and may also constitute “forward-looking statements” within the meaning of United States securities laws (collectively, “forward-looking statements”). Forward-looking statements in this release include, but are not limited to, statements regarding the use of proceeds from the completed financing, the Company’s future, R&D programs, development activities, and the potential of its technology. Forward-looking statements are based on the current expectations, estimates, beliefs and assumptions of management as of the date hereof. Such statements are subject to several known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the use of proceeds, market conditions, competition, development activities, pricing, and general economic conditions. Although the Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information contact:

SPARC AI Inc.
E-mail: investors@sparcai.com
Web: www.sparcai.com
Tel: (213) 459-3994

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.